Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB
Ratings Surperformance© - Laboratorios Farmaceuticos Rovi, S.A.

Ratings ESG MSCI

Ratings ESG MSCI - Laboratorios Farmaceuticos Rovi, S.A.

Ratings Laboratorios Farmaceuticos Rovi, S.A.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
Highlights: Laboratorios Farmaceuticos Rovi, S.A.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Laboratorios Farmaceuticos Rovi, S.A.
  • The company's enterprise value to sales, at 3.83 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Valuation

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Consensus

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Business Predictability

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.

Rating Revisions

Laboratorios Farmaceuticos Rovi, S.A. SectorUnited Kingdom

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Laboratorios Farmaceuticos Rovi, S.A.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
333.03Cr
BBB
1,04300Cr
A
62TCr
BBB
48TCr
AAA
-
35TCr
AA
34TCr
AA
27TCr
AAA
24TCr
A
22TCr
BBB
18TCr
AA
Average 37.5TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ROVI Stock
  4. 0ILL Stock
  5. Ratings Laboratorios Farmaceuticos Rovi, S.A.